MT-TL1 — Mitochondrially Encoded tRNA-Leu (UUA/G) 1

Illustration of the eye cross-section showing the retina at the back of the eye

The MT-TL1 gene is like an instruction manual for making a special tool called a transfer RNA (tRNA), which works inside the energy factories of your cells, known as mitochondria. This tool helps build important proteins that your mitochondria need to convert the food you eat and the oxygen you breathe into energy. Because mitochondria are the powerhouses of the cell, they are especially important for organs that require a lot of energy, like your brain, muscles, heart, and eyes. When there is a mutation or change in the MT-TL1 gene, the tRNA tool doesn't work correctly. This means your mitochondria can't build the proteins they need, and as a result, they can't produce enough energy for your cells. This lack of energy can cause a variety of health problems depending on which organs are most affected. For example, it can lead to muscle weakness, extreme fatigue, hearing loss, diabetes, and in severe cases, stroke-like episodes or heart problems. Because mitochondria are inherited only from mothers, these conditions are passed down from a mother to her children.

Gene description: The MT-TL1 gene provides instructions for making a specific transfer RNA (tRNA) designated as tRNALeu(UUR), which is located in the mitochondria. This tRNA is essential for assembling proteins involved in oxidative phosphorylation, the process that generates the cell's main energy source, ATP. Mutations in this gene disrupt mitochondrial energy production and lead to various multisystemic diseases.

Patient and family guide: The MT-TL1 gene is like an instruction manual for making a special tool called a transfer RNA (tRNA), which works inside the energy factories of your cells, known as mitochondria. This tool helps build important proteins that your mitochondria need to convert the food you eat and the oxygen you breathe into energy. Because mitochondria are the powerhouses of the cell, they are especially important for organs that require a lot of energy, like your brain, muscles, heart, and eyes. When there is a mutation or change in the MT-TL1 gene, the tRNA tool doesn't work correctly. This means your mitochondria can't build the proteins they need, and as a result, they can't produce enough energy for your cells. This lack of energy can cause a variety of health problems depending on which organs are most affected. For example, it can lead to muscle weakness, extreme fatigue, hearing loss, diabetes, and in severe cases, stroke-like episodes or heart problems. Because mitochondria are inherited only from mothers, these conditions are passed down from a mother to her children.

Gene function: The MT-TL1 gene encodes the mitochondrial transfer RNA for leucine (UUR). During protein assembly within mitochondria, this tRNA molecule attaches to the amino acid leucine and inserts it into the appropriate locations in growing proteins. These proteins are crucial components of the oxidative phosphorylation system, which produces ATP.

Protein structure: As a transfer RNA (tRNA) gene, MT-TL1 does not encode a protein. Instead, it produces a non-coding RNA molecule that folds into a characteristic cloverleaf secondary structure and an L-shaped tertiary structure, which is essential for its function in carrying the amino acid leucine during mitochondrial protein synthesis.

Molecular function: The molecular function of the MT-TL1 gene product, tRNALeu(UUR), is to act as a triplet codon-amino acid adaptor during mitochondrial translation. It specifically recognizes the UUR (UUA or UUG) codons on messenger RNA and delivers the corresponding amino acid, leucine, to the ribosome for incorporation into nascent polypeptide chains. Proper modification of the wobble uridine in the anticodon is critical for accurate codon recognition and efficient translation of mitochondrial proteins essential for oxidative phosphorylation.

Mutation spectrum: The mutation spectrum of MT-TL1 primarily consists of single nucleotide substitutions (point mutations), with the A3243G transition being the most common, responsible for about 80% of MELAS cases and 85% of MIDD cases. Other point mutations include T3271C, A3302G, and T3291C. Small deletions, such as m.3274_3275delAC, have also been reported. These mutations are typically heteroplasmic, meaning mutated and wild-type mtDNA coexist within cells.

Clinical significance: Mutations in the MT-TL1 gene, such as the common A3243G mutation, impair the ability of mitochondria to make proteins, use oxygen, and produce energy. This mutation reduces the ability of tRNALeu(UUR) to add leucine to proteins being assembled, slowing protein production. In beta cells, this impairs the mitochondria's ability to trigger insulin release, leading to diabetes. In other tissues, the impaired oxidative phosphorylation and energy production lead to multisystemic disorders affecting the brain, muscles, heart, and eyes, causing conditions like MELAS, MIDD, and MERRF.

Inheritance: Mitochondrial (Maternal)

Chromosomal location: Mitochondrial (MT: 3,230-3,304)

Research and therapeutic approaches: Currently, there are no definitive cures for diseases caused by MT-TL1 mutations, and treatments are primarily supportive, focusing on managing symptoms (e.g., insulin for diabetes, cochlear implants for deafness). Experimental therapeutic approaches being investigated include gene therapy strategies such as allotopic expression (importing functional tRNA from the cytoplasm into mitochondria), mitochondrial targeted nucleases (like TALENs or ZFNs) to selectively eliminate mutant mtDNA and shift heteroplasmy towards wild-type, and metabolic therapies aimed at bypassing defective respiratory chain complexes.